Functions of 3′UTRs and cytoplasmic compartmentalization
Chen, X., Fansler, M.M., Janjoš, U., Ule, J., and Mayr, C. (2024). The FXR1 network acts as signaling scaffold for actomyosin remodeling. Cell, in press. Also on bioRxiv, 2023.2011.2005.565677.
Luo, Y., Pratihar, S., Horste, E.H., Mitschka, S., Mey, A.S.J.S., Al-Hashimi, H.M., and Mayr, C. (2023). mRNA interactions with disordered regions control protein activity. bioRxiv, 2023.2002.2018.529068.
Horste, E.L., Fansler, M.M., Cai, T., Chen, X., Mitschka, S., Zhen, G., Lee, F.C.Y., Ule, J., and Mayr, C. (2023). Subcytoplasmic location of translation controls protein output. Mol Cell 83, 4509-4523.e4511.
Chen, X., and Mayr, C. (2022). A working model for condensate RNA-binding proteins as matchmakers for protein complex assembly. Rna 28, 76-87.
Ma W, Zhen G, Xie W, Mayr C. In vivo reconstitution finds multivalent RNA-RNA interactions as drivers of mesh-like condensates. eLife, 10:e64252 (2021). PMID: 33650968
Mitschka, S., and Mayr, C. (2021). Endogenous p53 expression in human and mouse is not regulated by its 3’UTR. eLife 10.
Mitschka, S., Fansler, M.M., and Mayr, C. (2021). Generation of 3’UTR knockout cell lines by CRISPR/Cas9-mediated genome editing. Methods in enzymology 655, 427-457.
Lee SH, Mayr C. Gain of additional BIRC3 protein functions through 3′UTR-mediated protein complex formation. Mol Cell 74, 701-712 (2019). PMID: 30948266
Ma W, Mayr C. A membraneless organelle associated with the endoplasmic reticulum enables 3′UTR-mediated protein-protein interactions. Cell 175, 1492-1506 (2018). PMID:30449617. PDF
Mayr C. Protein complexes assemble while they are being made. Nature (2018). PMID:30194367. PDF
Mayr C. What are 3’UTRs doing? Cold Spring Harbor Perspectives in Biology (2018). Sept 4. PMID: 30181377
Mayr C. Regulation by 3′-Untranslated Regions. Annu Rev Genet 51:171-194 (2017). PMID: 28853924
Mayr C. Evolution and Biological Roles of Alternative 3’UTRs. Trends Cell Biol 26, 227-237 (2016). PMID:26597575 PDF
Berkovits BD, Mayr C. Alternative 3’UTRs act as scaffolds to regulate membrane protein localization. Nature 522, 363-367 (2015). Epub 2015 Apr 20. PMID:25896326 PDF
- Highlighted in Nature Reviews Molecular Cell Biology PDF
Alternative polyadenylation
Fansler, M.M., Mitschka, S., and Mayr, C. (2024). Quantifying 3′UTR length from scRNA-seq data reveals changes independent of gene expression. Nature communications 15, 4050.
Mitschka, S., Mayr, C. Context- specific regulation and function of mRNA alternative Polyadenylation (2022). Nature reviews Molecular Cell Biology, 12: 779-796
Kwon, B., Fansler, M.M., Patel, N.D., Lee, J., Ma, W., and Mayr, C. (2022). Enhancers regulate 3’ end processing activity to control expression of alternative 3’UTR isoforms. Nature communications 13, 2709
Lee SH*, Singh I*, Tisdale S, Abdel-Wahab O, Leslie CS, Mayr C. Widespread intronic polyadenylation inactivates tumor suppressor genes in leukemia. Nature 561, 127-131 (2018). PMID:30150773. PDF
- Highlighted in Nature Reviews Cancer PDF
- Highlighted in Cancer Discovery PDF
- Highlighted in Trends in Cancer PDF
Singh I, Lee SH, Sperling AS, Samur MK, Tai YT, Fulciniti M, Munshi NC, Mayr C, Leslie CS. Widespread intronic polyadenylation diversifies immune cell transcriptomes. Nat commun 9: 1716 (2018). PMCID: PMC5928244 PDF
Lianoglou S, Garg V, Yang JL, Leslie CS, Mayr C. Ubiquitously transcribed genes use alternative polyadenylation to achieve tissue-specific expression. GenesDev 27, 2380-2396 (2013). PMID:24145798 PDF
- Selected by Science Signaling as one of the Breakthroughs of 2013 PDF
- Recommended by the Faculty of 1000
Mayr C, Bartel DP. Widespread shortening of 3’UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 138, 673-684 (2009). PMID:19703394 PDF
- Highlighted in Nature PDF
- Highlighted in Nature Reviews Genetics PDF
- Designated as “Exceptional” by the Faculty of 1000
Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP, Burge CB. Alternative isoform regulation in human tissue transcriptomes. Nature 456,470-476 (2008). PMID:18978772
- Designated as “Exceptional” by the Faculty of 1000
Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315, 1576-1579 (2007). Epub 2007 Feb 22. PMID:17322030 PDF
- Highlighted in Nature Reviews Cancer PDF
- Highlighted in Journal of the American Chemical Society PDF
- Highlighted in Science PDF
Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF. miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A 104, 7080-7085 (2007). Epub 2007 Apr 16. PMID:17438277
Immunotherapy and prognostic factors in CLL
Pallasch CP, Patz M, Park YJ, Hagist S, Eggle D, Claus R, Debey-Pascher S, Schulz A, Frenzel L, Claasen J, Kutsch N, Krause G, Mayr C, Rosenwald A, Plass C, Schultze JL, Hallek M, Wendtner CM. miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAG1 in chronic lymphocytic leukemia. Blood 114, 3255-3264 (2009). Epub 2009 Aug 19.
Wiesner M, Zentz C, Mayr C, Wimmer R, Hammerschmidt W, Zeidler R, Moosmann A. Conditional immortalization of human B cells by CD40 ligation. PloS ONE 3, e1464 (2008). PMID:18213373
Bund D, Mayr C, Kofler DM, Hallek M, Wendtner CM. CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes. Exp Hematol 35, 920-930 (2007). PMID:17533046
Bund D, Mayr C, Kofler DM, Hallek M, Wendtner CM. Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells. Exp Hematol 34, 860-869 (2006). PMID:16797413
Kofler DM, Mayr C, Wendtner CM. Current status of immunotherapy in B cell malignancies. Curr Drug Targets 7, 1371-1374 (2006). PMID:17073599
Mayr C, Bund D, Schlee M, Bamberger M, Kofler DM, Hallek M, Wendtner CM. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes. Exp Hematol 34, 44-53 (2006). PMID:16413390
Mayr C, Speicher MR, Kofler DM, Buhmann R, Busch R, Strehl J, Hallek M, Wendtner CM. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 107, 742-751 (2006). Epub 2005 Sep 22. PMID:16179374
Mayr C, Kofler DM, Büning H, Bund D, Hallek M, Wendtner C-M. Transduction of CLL cells by CD40 ligand (CD40L) enhances an antigen specific immune recognition by autologous T cells. Blood 106, 3223-3226 (2005). Epub 2005 Jul 12. PMID:16014560
Mayr C, Bund D, Schlee M, Moosmann A, Kofler DM, Hallek M, Wendtner C-M. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL) which allows expansion of specific CD8+ autologous T lymphocytes. Blood 105, 1566-1573 (2005). Epub 2004 Oct 7. PMID:15471955
Kofler DM, Büning H, Mayr C, Bund D, Baumert J, Hallek M, Wendtner CM. Engagement of the B-cell antigen receptor (BCR) allows efficient transduction of ZAP-70 positive B-CLL cells by recombinant adeno-associated virus (rAAV) vectors. Gene Ther 11, 1416-1424 (2004). PMID:15269708
Wendtner CM, Kofler DM, Mayr C, Bund D, Hallek M. The potential of gene transfer into primary B-CLL cells using recombinant virus vectors. Leuk Lymphoma 45, 897-904 (2004). PMID:15291346
Strehl J, Mey U, Glasmacher A, Djulbegovic B, Mayr C, Gorschluter M, Ziske C, Schmidt-Wolf IG. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin’s lymphoma is superior to conventional chemotherapy in selected patients: a meta-analysis. Haematologica 88, 1304-1315 (2003). PMID:14607760
Mayr C, Radzom S, Dreyling M. Neurotoxicity under chemotherapy with high doses of cytarabine. Arzneimitteltherapie 19, 296-298 (2001).
Hildebrandt M, Rose M, Mayr C, Arck P, Schüler C, Reutter W, Salama A, Klapp BF. Dipeptidyl peptidase IV (DPP IV, CD 26) in patients with mental eating disorders. Adv Exp Med Biol 477, 197-204 (2000). PMID:10849747
Hildebrandt M, Rose M, Mayr C, Schüler C, Reutter W, Salama A, Klapp BF. Alterations in expression and in serum activity of dipeptidyl peptidase IV (DPP IV, CD 26) in patients with hyporectic eating disorders. Scand J Immunol 50, 536-541 (1999). PMID:10564557